Antibodies to heat shock protein 90 in osteosarcoma patients and chemotherapy response
Author Information
Author(s): Trieb K, Gerth R, Holzer G, Grohs J G, Berger P, Kotz R
Primary Institution: Department of Orthopedics, University of Vienna
Hypothesis
The presence of anti-Hsp90 antibodies in osteosarcoma patients correlates with their response to neoadjuvant chemotherapy.
Conclusion
Patients with anti-Hsp90 antibodies had a better response to chemotherapy, while those without developed metastases.
Supporting Evidence
- Presence of anti-Hsp90 antibodies correlated with a better response to neoadjuvant chemotherapy.
- Absence of these antibodies correlated with the development of metastases.
Takeaway
If osteosarcoma patients have certain antibodies, they might respond better to treatment. If they don't have these antibodies, they could get worse.
Methodology
Sera from 20 high-grade osteosarcoma patients were tested for anti-Hsp90 antibodies using enzyme-linked immunosorbent assay (ELISA).
Participant Demographics
High-grade osteosarcoma patients.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website